Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Veenat 100

Anticancer-Cancer-Treatment-natco-Imatinib-100mg-Veenat

Availability: In stock

Special Price $ 299

BRAND : Veenat
STRENGTH : 100mg
INGREDIENT : Anticancer-Cancer-Treatment-natco-Imatinib-100mg-Veenat
COMPANY NAME : Natco
COUNT : 120 Tablets



Description of Veenat 100

Product details:
Brand name: Veenat
Generic name: Imatinib mesylate
Manufacturer: Natco
Strength: 100mg
Category: Anti-neoplastic agent
Container: 30 tablets in a bottle
Product Description:
Veenat tablet is an anti cancer medicine which is useful for treating;
• Advanced myelogenous leukemia (CML),
• Gastrointestinal stromal tumors (GISTs) and a number of malignancies
Veenat is a tyrosine kinase inhibitor that prohibits BCR-ABL kinase produced by chromosomal rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia
PDG-derived tyrosine kinase that are expressed in gastrointestinal stromal tumor
Veenat is used as monotherapy, or it may combine with some other medicine in the conditions of certain types of cancer or bone marrow disorders.

Pharmacology of Veenat 100

Mechanism of action:
Veenat contains an active chemical substance known as Imatinib mesylate; it is an inhibitor of certain tyrosine kinase enzymes.
Veenat prohibits BCR-ABL tyrosine kinase (atypical enzyme produced by Philadelphia chromosome abnormality in CML)
Veenat obstruct the multiplication and promote the apoptosis in BCR-ABL positive cells in addition to fresh leukemia cells from Philadelphia chromosome positive CML
Veenat also prohibits tumor growth of BCR-ABL transacted murine myeloid cells along other BCR-ABL positive leukemia CML in blast crisis
Veenat inhibits receptor tyrosine kinase for platelet-derived growth factor (PDGF), stem cell factor (SCF) and PDGF and SCF mediated cellular events get prohibited.
Pharmacodynamic:
 Veenat 100mg tablets is primarily used to treat chronic myelogenous leukemia (CML), Veenat a 2-phenylaminopyrimidine analog, it acts as a prohibitor of tyrosine kinase enzyme.
 In malignancy conditions, Philadelphia chromosome leads to fusing of protein with BCR (breakpoint cluster region). Veenat used to reduced Bcr-Abl activity
Pharmacokinetic:
Absorption:
After an oral administration of Veenat tablets, it is largely absorbed within 2-4 hours. The bioavailability of Veenat tablets is about 98%.
Distribution:
Imatinib is highly bound to the human plasma protein almost range of 95%. It is mostly bound to albumin and α1-acid glycoprotein.
Metabolism:
The major enzyme which is essential for metabolism of Veenat tablet is CYP3A4.
Active metabolite of Imatinib is N-demethylated piperizine derivative
Excretion:
The elimination of Imatinib is predominantly occurred in feces.
Nearly 81% of the drug excreted within 7 days through feces and 13% of drug through urine.
The half life time of Imatinib and active metabolite N-demethyl derivative (CGP74588) are around 18 and 40 hours respectively

Indication of Veenat 100

Veenat tablets are primarily indicated for the treatment of;
Aggressive systemic mastocytosis
Chronic esinophillic leukemia
Dermatofibrosarcoma protuberans
Gastrointestinal stromal tumors
Hyperesinophillic syndrome
Myelodysplastic syndrome
Myeloproliferative disease
Philadelphia chromosome positive acute lymphoblastic leukemia
Philadelphia chromosome positive chronic myeloid leukemia

Dose & Dosage's of Veenat 100

The prescribed dose of tablet Veenat is 400mg or 600mg as a single dose. Whereas 800mg which is administered as 400mg twice daily.
Veenat tablets should be taken with food
The recommended dose for following conditions;
Acute lymphoblastic leukemia:
In adults, the recommended dose is 600mg should be taken orally as a single dose.
Myelodysplastic/Myeloproliferative diseases:
The prescribed dose is 400mg PO qDay
Hyperesinophillic syndrome:
In this condition, prescribed dose is 400mg PO qDay
Chronic myeloid leukemia:
Chronic phase: In newly diagnosed patients, the dose of Veenat tablet is 400mg should be orally taken as a single dose.
If chronic phase is failed with the treatment of interferon alpha therapy; dose is increased to 600mg per day.
Accelerated phase: 600mg PO qDay; dose should be vary to 400mg PO as twice daily if there is no severe adverse drug reaction or non leukemia associated neutropenia or thrombocytopenia.
Dermatofibrosarcoma protuberans:
Recommended dose is 400mg PO q12hr
Mastocytosis:
Without D816V c-kit mutation: 100mg per oral for qDay
c-kit mutational status unknown: 400mg per oral qDay
ASM related with esinophillic: 100mg PO qDay initially increased to 400mg/day.
Gastrointestinal stromal tumors
The prescribed dose of the tablet Veenat is 400mg should be taken orally as a twice daily
In pediatric:
Chronic myeloid leukemia:
<1 year: the safety and efficacy of the drug has not been established
≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day
Acute lymphoblastic leukemia:
<1 year: the safety and efficacy of the drug has not been established
≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day
Missed dose:
If patient fail to take Veenat tablet, patient should administered within a time.
Otherwise, tablet should be discontinued and follow the next drug schedule.

Side Effects of Veenat 100

Cardiac disorders:
Palpitations, pericardial effusion, congestive cardiac failure, tachycardia, pulmonary edema, arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris
Vascular disorders:
Flushing, hemorrhage, hypertension, peripheral coldness, Reynaud’s phenomenon, elevated LDH levels
Skin disorders:
Dry skin, alopecia, face edema, Erythema, photosensitivity reactions, nail disorder, purpura, psoriasis, rashes, vascular rash, Stevens Johnson syndrome, acute febrile neutrophillic dermatosis.
Gastrointestinal disorders:
Abdominal distension, gastro esophageal reflux, dry mouth, gastritis, gastric ulcer, stomatitis, mouth ulcer, eructation, esophagitis, dysphasia, and pancreatitis
General disorders:
Weakness, anasarca, chills, malaise
Blood and lymphatic system:
Pancytopenia, febrile neutropenia, Lymphopenia, esinophillia, thrombocythemia, bone marrow depression, lymphadenopathy, hemolytic anemia, Aplastic anemia
Hepatobiliary:
Hepatitis, jaundice, hepatic failure, hepatic necrosis
Immune system:
Angioedema
Infection and infestation:
Herpes simplex, herpes zoster, cellulitis, urinary tract infection (UTI), gastroenteritis, sepsis
Metabolism and nutrition:
Weight decreased, loss of appetite, dehydration, gout, hyperuricemia, hypocalcaemia, hyperglycemia, hyponatremia, hyperkelamia, hypomagnesemia
Musculoskeletal:
Joint swelling, muscle stiffness, muscular weakness, arthritis
Nerve system:
Paresthesia, hypesthesia, syncope, peripheral neuropathy, somnolence, tremor
Renal and urinary disorders:
Renal failure, frequency of urine will increased, Hematuria, renal pain
Reproductive system:
Breast enlargement, menorrhagia, sexual dysfunction, gynecomastia, erectile dysfunction, menstruation irregular, nipple pain, scrotal edema
Respiratory:
Epistaxis, pleural effusion, interstitial pneumonitis, pulmonary fibrosis, pulmonary hypertension, pulmonary hemorrhage
Eye, ear and labyrinth disorders:
Conjunctivitis, vision blurred, orbital edema, conjuctival hemorrhage, dry eye, vertigo, tinnitus, eye irritation, eye pain, scleral hemorrhage, retinal hemorrhage, papilla edema, glaucoma

Contraindication of Veenat 100

Hypersensitive reaction to Imatinib mesylate and other excipients present in Veenat tablets

Drug Interaction of Veenat 100

Veenat tablets are primarily indicated for the treatment of; Aggressive systemic mastocytosis Chronic esinophillic leukemia Dermatofibrosarcoma protuberans Gastrointestinal stromal tumors Hyperesinophillic syndrome Myelodysplastic syndrome Myeloproliferative disease Philadelphia chromosome positive acute lymphoblastic leukemia Philadelphia chromosome positive chronic myeloid leukemia

Precaution of Veenat 100

Caution with use in hepatic impairment patients
Avoid combination with strong CYP3A4 inducers
Risk of severe CHF or ventricular dysfunction
Hemorrhage occurs
Growth retardation occurs in children

Usage & Safety profile of Veenat 100 Pregnancy & Lactation

Pregnancy category: D Veenat should not recommended to pregnant and breast feeding mothers, it can able to cause fetal malformations and cause fetal harm The metabolites excreted in human milk

Storage of Veenat 100

Veenat tablet container should be stored in cool and dry place
It should be keep away from moisture, heat and light